AstraZeneca grants Recordati commercial rights to Seloken

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Recordati S.p.A. (Milan:REC) European commercial rights to Seloken metoprolol tartrate, Seloken ZOK metoprolol succinate and Logimax metoprolol succinate/felodipine for $300 million up front. AstraZeneca will manufacture and supply the products and is eligible to receive double-digit royalties.

Seloken is a selective adrenergic receptor beta 1 (ADRB1) blocker marketed to treat hypertension, angina and heart failure. Logimax, a fixed-dose combination of metoprolol succinate and felodipine, a calcium channel blocker, is marketed to treat hypertension...